Dear Diplomates,

It is with great excitement that I write to you as Chair of the American Board of Nuclear Medicine. I am deeply honored and grateful for the opportunity to serve you in this capacity and am indebted to the work of our prior Chairs. Most recently Dr. Grady set a very high bar that I hope to match.

The last year has been incredibly exciting for the field of Nuclear Medicine and the future promises to be even brighter. We have seen the FDA approval of new diagnostic and therapeutic radiopharmaceuticals. Furthermore, we are witnessing an unprecedented level of investment in radiopharmaceutical development with numerous large multi-center clinical trials ongoing. This highlights the ongoing and growing need for well-trained and well-qualified practitioners to bring these new agents to our patients. ABNM certification remains gold standard evidence of qualification to practice Nuclear Medicine at a high level.

At the same time, these new radiopharmaceuticals and techniques require ongoing learning by our Diplomates. The ABNM is committed to assisting our Diplomates in learning about cutting edge procedures and showing evidence of such ongoing learning. Indeed, with the launch of the CertLink pilot, we have given our Diplomates the opportunity to participate in a program that simultaneously assesses and disseminates knowledge of the techniques that are relevant in today's practice. We have been thrilled by the community's response to CertLink—enrollment and early feedback have both been strong. However, enrollment remains less than it could be. I would strongly encourage all ABNM Diplomates not currently participating in the CertLink pilot to please consider enrolling. If you have questions, please see our CertLink FAQ page or call the ABNM office.

With the inclusion of state-of-the-art content in CertLink, successful participation in CertLink will provide a Diplomate with strong evidence that s/he is providing quality, cutting-edge care.

In addition to our current Diplomates, the ABNM remains committed to ensuring excellent training for the future practitioners of Nuclear Medicine. We continue to collaborate diligently with stakeholders in graduate medical education to allow Nuclear Medicine training to evolve with changes in practice demands. 2017 saw an increase in the number of physicians sitting for the certification exam. Congratulations to our new Diplomates! The ABNM will continue to do all that we can to maintain the steady stream of new Diplomates required for the field to continue to thrive. The future of Nuclear Medicine is bright and I am thrilled at the opportunity to serve as the Chair of the American Board of Nuclear Medicine at this exciting time.